2018第三届国际肿瘤精准医学高峰论坛成功举办

[23] Roymans D, Alnajjar SS, Battles MB, et al. Therapeutic efficacy of a

respiratory syncytial virus fusion inhibitor. Nat Commun, 2017, 8(1): 167.

[24] Israel S, Rusch S, DeVincenzo J, et al. Effect of oral JNJ-53718678

(JNJ-678) on disease severity in healthy adult volunteers experimentally inoculated with live respiratory syncytial virus (RSV): a placebo-controlled challenge study//Oh, Those Pesky Viruses! 2016. https://idsa.confex.com/idsa/2016/webprogram/Paper59339.html. [25] Janssen Research & Development, LLC. A study to assess the relative

oral bioavailability of a single dose of JNJ-53718678 administered as oral concept formulation compared to the current oral solution and to assess the effect of food on the pharmacokinetics of oral concept formulation. 2016-10-26 (2018-04-13) [2018-10-25]. https://clinicaltrials. gov/ct2/show/NCT02945007.

[26] Toovey S, Wu J, Wang V, et al. Safety and pharmacokinetics in

healthy volunteers of the anti-RSV antiviral AK0529//1st International Meeting on Respiratory Pathogens, Singapore 2015.

[27] Ark Biosciences Inc. Viral inhibition in children for treatment of RSV.

2016 (2018-07-02) [2018-10-25]. https://clinicaltrials.gov/ct2/show/ NCT02654171.

[28] A Draffan, S Bond, J Fenner, et al. (Eds.), Preclinical characterization

of an orally bioavailable fusion inhibitor, BTAC585, for the treatment of RSV infection//54th Interscience Conference on Antimicrobial

Agents and Chemotherapy (ICAAC) Meeting, Washington, DC, 2014. [29] Vaxart (Biota Pharma Europe Limited). Safety, efficacy and

pharmacokinetics of BTA-C585 in a RSV viral challenge study. 2016-05-24 (2018-05-30) [2018-10-25]. https://clinicaltrials.gov/ct2/ show/NCT02718937.

[30] Nikitenko AA, Raifeld YE, Wang TZ. The discovery of RFI-641 as a

potent and selective inhibitor of the respiratory syncytial virus. Bioorg Med Chem Lett, 2001, 11(8):1041-1044.

[31] Olszewska W, Openshaw P. Emerging drugs for respiratory syncytial

virus infection. Expert Opin Emerg Drugs, 2009, 14(2):207-217. [32] Wyde PR, Laquerre S, Chetty SN, et al. Antiviral efficacy of VP14637

against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol. Antivir Res, 2005, 68(1):18-26. [33] Roymans D, De Bondt HL, Arnoult E, et al. Binding of a potent

small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein. Proc Natl Acad Sci U S A, 2010, 107(1):308-313.

[34] Battles MB, Langedijk JP, Furmanova-Hollenstein P, et al. Molecular

mechanism of respiratory syncytial virus fusion inhibitors. Nat Chem Biol, 2016, 12(2):87-93.

[35] Ispas G, Koul A, Verbeeck J, et al. Antiviral activity of TMC353121, a

respiratory syncytial virus (RSV) fusion inhibitor, in a non-human primate model. PLoS One, 2015, 10(5):e0126959.

·协会之窗·

2018第三届国际肿瘤精准医学高峰论坛成功举办

2018 第三届国际肿瘤精准医学高峰论坛于 2018 年 10 月 12 – 14 日在深圳成功举办，来自国内外的 500 余位参会代表相聚鹏城，共同探讨肿瘤精准医疗的最新研究进展及未来将面临的机遇和挑战。

随着生命科技和信息技术的日新月异及人类对癌症发生发展的理解日益加深，当前“精准医学”已成为肿瘤研究最前 沿、最受关注的热点，是肿瘤治疗发展的新方向。这种新型医学理念与医疗模式，正在给全球的医疗和健康产业带来巨大的变革。

本次会议是肿瘤精准医疗领域的一次盛会。天津市肿瘤研究所郝希山院士、北京大学医学部詹启敏院士、美国医学科 学院 Raju Kucherlapati 院士出席会议并作主题报告。来自中、美、日等国的顶尖专家及知名学者分享肿瘤精准治疗最新动态和发展模式，以及实体瘤和血液恶性肿瘤治疗应用的难点、要点及前景。本次论坛对推动我国肿瘤精准治疗思路的拓展，为相关专家和行业领导者搭建分享学术成果和经验交流的国际化平台起到促进交流、加强合作、推动精准医学快速发展和进步的作用。